At the MedCity CONVERGE conference in Philadelphia Wednesday, Case Western University bioethics professor Insoo Hyun explored the ethical issues raised by use of technologies like CRISPR-Cas9 in humans.
Next month's MedCity CONVERGE conference will include a panel of experts who will talk about the cost and value of new cancer treatments like cell therapies and immunotherapies.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Me-too drugs and ill-defined AI are less interesting than unmet need and AI with supporting evidence.
Panelists highlight Roche's acquisition of Flatiron Health in February and use of AI/ML in drug development.
Blood-based cancer tests have market, but more evidence may be needed to verify validity and utility.
Panel at MedCity CONVERGE discussed the practical applications of AI in the treatment of cancers.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The MedCity CONVERGE conference in Philadelphia on July 11-12 will take a closer look at how companies like Deep 6 AI are making their mark at the intersection of artificial intelligence and cancer care.
As providers and payers shift to new ways of measuring and compensating for the cost and quality of patient care, population health management has become a primary mechanism for making the transition sustainably.
At the MedCity CONVERGE conference in Philadelphia on July 11-12, a panel of experts will discuss how to make the care journey a bit more bearable for those living with cancer.
A panel at MedCity CONVERGE in July will discuss the challenges preventing precision medicine from reaching its full potential and how we can overcome them.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Targeted therapies have potential to be highly effective. The challenge is finding patients to enroll in clinical trials.
MedCity CONVERGE speaker discusses the challenges facing reimbursement and how ECRI Institute simplifies it.
Experts discuss the multitude of factors feeding high drug prices and some of the solutions that policymakers have proposed.
The collaboration with MD Anderson was a year in the making and will be Oncora Medical's biggest endeavor to date, according to Oncora Medical CEO David Lindsay.
Check out elevator pitches from healthcare startups across digital health and life sciences.